|
1.
|
American Cancer Society: Adult soft tissue
cancer. What are the key statistics about soft tissue sarcomas?
http://www.cancer.org/cancer/sarcoma-adultsofttissuecancer/detailedguide/sarcoma-adult-soft-tissue-cancer-key-statistics.
Last revised October 2, 2012. Accessed January 21, 2013.
|
|
2.
|
American Cancer Society: Bone cancer. What
are the key statistics about bone cancer? http://www.cancer.org/cancer/bonecancer/detailedguide/bone-cancer-key-statistics.
Last revised November 29, 2012. Accessed January 21, 2013.
|
|
3.
|
Papagelopoulos PJ, Galanis E, Frassica FJ,
Sim FH, Larson DR and Wold LE: Primary fibrosarcoma of bone.
Outcome after primary surgical treatment. Clin Orthop Relat Res.
373:88–103. 2000.PubMed/NCBI
|
|
4.
|
Benassi MS, Gamberi G, Magagnoli G,
Molendini L, Ragazzini P, Merli M, Chiesa F, Balladelli A, Manfrini
M, Bertoni F, Mercri M and Picci P: Metalloproteinase expression
and prognosis in soft tissue sarcomas. Ann Oncol. 12:75–80. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
6.
|
Liotta LA, Tryggvason K, Garbisa A, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Stetler-Stevenson WG: The role of matrix
metalloproteinases in tumor invasion, metastasis, and angiogenesis.
Surg Oncol Clin N Am. 10:383–392. 2001.PubMed/NCBI
|
|
8.
|
Stetler-Stevenson WG: Type IV collagenases
in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Sato T, Sakai T, Noguchi Y, Takta M,
Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion
of human uterine cervical carcinoma cells by augmenting the
expression and activation of stromal matrix metalloproteinases.
Gynecol Oncol. 92:47–56. 2004. View Article : Google Scholar
|
|
10.
|
Pyke C, Kristensen P, Ralfkiaer E,
Gröndahl-Hansen J, Eriksen J, Blasi F and Danø K: Urokinase-type
plasminogen activator is expressed in stromal cells and its
receptor in cancer cells at invasive foci in human colon
adenocarcinomas. Am J Pathol. 138:1059–1067. 1991.PubMed/NCBI
|
|
11.
|
Harvey P, Clark IM, Jourand MC, Warn RM
and Edwards DR: Hepatocyte growth factor/scatter factor enhances
the invasion of mesothelioma cell lines and the expression of
matrix metalloproteinases. Br J Cancer. 83:1147–1153. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Liu Z, Ivanoff A and Klominek J:
Expression and activity of matrix metalloproteases in human
malignant mesothelioma cell lines. Int J Cancer. 91:638–643. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Vincenti MP, White LA, Schroen DJ, Benbow
U and Brinckerhoff CE: Regulating expression of the gene for matrix
metalloproteinase-1 (collagenase): mechanisms that control enzyme
activity, transcription and mRNA stability. Crit Rev Eukaryot Gene
Expr. 6:391–411. 1996. View Article : Google Scholar
|
|
14.
|
Rutkowski P, Kaminska J, Kowalska M, Ruka
W and Steffen J: Cytokine and cytokine receptor serum levels in
soft tissue sarcoma patients: correlations with
clinico-pathological features and prognosis. Int J Cancer.
100:463–471. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Ray JM and Stetler-Stevenson WG: The role
of matrix metalloproteinase and their inhibitors in tumour
invasion, metastasis and angiogenesis. Eur Respir J. 7:2062–2072.
1994.PubMed/NCBI
|
|
16.
|
Apodaca G, Rutka JT, Bouhana K, Berens ME,
Giblin JR, Rosenblum ML, McKerrow JH and Banda MJ: Expression of
metalloproteinases and metalloproteinase inhibitors by fetal
astrocytes and glioma cells. Cancer Res. 50:2322–2329.
1990.PubMed/NCBI
|
|
17.
|
Linder C, Linder S, Munck-Wickland E and
Strander H: Independent expression of serum vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor (bFGF) in
patients with carcinoma and sarcoma. Anticancer Res. 18:2063–2068.
1998.PubMed/NCBI
|
|
18.
|
Graeven U, Andre N, Achilles E, Zornig C
and Schmeigel W: Serum levels of vascular endothelial growth factor
and basic fibroblast growth factor in patients with soft-tissue
sarcoma. J Cancer Res Clin Oncol. 125:577–581. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Rutkowski P, Kaminska J, Kowalska M, Ruka
W and Steffen J: Cytokine and cytokine receptor serum levels in
adult bone sarcoma patients: correlations with local tumor extent
and prognosis. J Surg Oncol. 84:151–159. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Niedzwiecki A, Roomi MW, Kalinovsky T and
Rath M: Micronutrient synergy - a new tool in effective control of
metastasis and other key mechanisms of cancer. Cancer Metastasis
Rev. 29:529–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Roomi MW, Monterrey JC, Kalinovsky T,
Niedzwiecki A and Rath M: Inhibition of invasion and MMPs by a
nutrient mixture in human cancer cell lines: a correlation study.
Exp Oncol. 32:243–248. 2010.PubMed/NCBI
|
|
22.
|
Roomi MW, Ivanov V, Kalinovsky T, Rath M
and Niedzwiecki A: In vivo and in vitro antitumor effect of
ascorbic acid, lysine, proline, arginine and green tea extract on
human fibrosarcoma cells HT-1080. Med Oncol. 23:105–112. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Roomi MW, Ivanov V, Kalinovsky T,
Niedzwiecki A and Rath M: In vitro and in vivo anti-tumor effect of
a nutrient mixture containing ascorbic acid, lysine, proline and
green tea extract on human synovial sarcoma cancer cells. JANA .
9:22006.
|
|
24.
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Comparative effects of EGCG, green tea and a
nutrient mixture on the patterns of MMP-2 and MMP-9 expression in
cancer cell lines. Oncol Rep. 24:747–757. 2010.PubMed/NCBI
|
|
25.
|
Rath M and Pauling L: Plasmin-induced
proteolysis and the role of apoprotein(a), lysine and synthetic
analogs. Orthomolecular Med. 7:17–23. 1992.
|
|
26.
|
Sun Z, Chen YH, Wang P, Zhang J, Gurewich
V, Zhang P and Liu JN: The blockage of high-affinity lysine binding
sites of plasminogen by EACA significantly inhibits
prourokinase-induced plasminogen activation. Biochem Biophys Acta.
1596:182–192. 2002.PubMed/NCBI
|
|
27.
|
Valcic S, Timmermann BN, Alberts DS,
Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect
of six green tea catechins and caffeine on the growth of four
selected human tumor cell lines. Anticancer Drugs. 7:461–468. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Mukhtar H and Ahmed N: Tea polyphenols:
prevention of cancer and optimizing health. Am J Clin Nutr.
71(Suppl 6): 1698–1704. 2000.PubMed/NCBI
|
|
29.
|
Yang GY, Liao J, Kim K, Yurtow EJ and Yang
CS: Inhibition of growth and induction of apoptosis in human cancer
cell lines by tea polyphenols. Carcinogenesis. 19:611–616. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Taniguchi S, Fujiki H, Kobayashi H, Go H,
Miyado K, Sadano H and Shimikawa R: Effect of (−) epigallocatechin
gallate, the main constituent of green tea, on lung metastasis with
mouse B16 melanoma cell lines. Cancer Lett. 65:51–54. 1992.
|
|
31.
|
Hara Y: Green Tea: Health Benefits and
Applications . Marcel Dekker; New York, Basel: 2001, View Article : Google Scholar
|
|
32.
|
Kawakami S, Kageyama Y, Fujii Y, Kihara K
and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion
and MMP 9 production of T24 human bladder cancer cells. Anticancer
Res. 21:213–219. 2001.PubMed/NCBI
|
|
33.
|
Morini M, Cai T, Aluigi MG, Noonan DM,
Masiello L, De Floro S, D'Agostinin F, Albini A and Fassima G: The
role of the thiol N-acetyl cysteine in the prevention of tumor
invasion and angiogenesis. Int J Biol Markers. 14:268–271.
1999.PubMed/NCBI
|
|
34.
|
Yoon SO, Kim MM and Chung AS: Inhibitory
effects of selenite on invasion of HT 1080 tumor cells. J Biol
Chem. 276:20085–20092. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Naidu KA, Karl RC and Coppola D:
Antiproliferative and proapoptotic effect of ascorbyl stearate in
human pancreatic cancer cells: association with decreased
expression of insulin-like growth factor 1 receptor. Dig Dis Sci.
48:230–237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Anthony HM and Schorah CJ: Severe
hypovitaminosis C in lung-cancer patients: The utilization of
vitamin C in surgical repair and lymphocyte-related host
resistance. Br J Cancer. 46:354–367. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Maramag C, Menon M, Balaji KC, Reddy PG
and Laxmanan S: Effect of vitamin C on prostate cancer cells in
vitro: effect on cell number, viability and DNA synthesis.
Prostate. 32:188–195. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Koh WS, Lee SJ, Lee H, Park C, Park MH,
Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH:
Differential effects and transport kinetics of ascorbate
derivatives in leukemic cell lines. Anticancer Res. 8:2487–2493.
1998.PubMed/NCBI
|
|
39.
|
Chen Q, Espey MG, Krishna MC, Mitchell JB,
Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic
ascorbic acid concentrations selectively kill cancer cells: action
as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl
Acad Sci USA. 102:13604–13609. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Nunez C, Ortiz de Apodaca Y and Ruiz A:
Ascorbic acid in the plasma and blood cells of women with breast
cancer. The effect of consumption of food with an elevated content
of this vitamin. Nutr Hosp. 10:368–372. 1995.(In Spanish).
|
|
41.
|
Kurbacher CM, Wagner U, Kolster B,
Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C)
improves the anti neoplastic activity of doxorubicin, cisplatin and
paclitaxel in human breast carcinoma cells in vitro. Cancer Lett.
103:183–189. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Cooke JP and Dzau VJ: Nitric oxide
synthase: Role in the genesis of vascular disease. Annu Rev Med.
48:489–509. 1997. View Article : Google Scholar : PubMed/NCBI
|
